Angiotensin-converting enzyme inhibition by hydroxamic zinc-binding idrapril in humans.

What Was Tested

The paper reports a study of Captopril, published as a randomized controlled trial.

The new angiotensin-converting enzyme (ACE) inhibitor idrapril acts by binding the catalytically important zinc ion to a hydroxamic group.

Blood pressure (BP) and heart rate (HR) remained unchanged.

Who Took Part

The study group was 8 men.

The age groups tagged for this paper are adults, men only.

How the Study Was Run

The researchers set it up as a randomized, double-blind and placebo-controlled study.

Random assignment meant chance, not the researchers, decided who got Captopril and who got the comparison, which limits bias.

Blinding on both sides kept the men and researchers unaware of who received Captopril.

A placebo (an inactive look-alike) gave the Captopril group a baseline to be compared against.

ACE inhibition in vivo was evaluated by changes in the ratio of specifically measured plasma angiotensin II (AngII) and AngI concentrations determined by high-performance liquid chromatography/radioimmunoassay (HPLC/RIA) techniques.

What Was Measured

The subject headings attached to it are Angiotensin II, Angiotensin-Converting Enzyme Inhibitors, Captopril, Cyclohexanecarboxylic Acids, Hydroxylamines, Peptidyl-Dipeptidase A and Renin.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Captopril in 8 men.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

The publication is from 1994 (Journal of cardiovascular pharmacology), a journal based in United States.

More context: all human trials.